General information about the research study
When was the study done? In an earlier study, 2 doses of different recipes of
RSV older adult (OA) vaccine were given to older
The study started in December 2020 and ended adults and their immune response and safety
in October 2021. were studied. Based on the results of that study,
a high-dose recipe was selected.
Why was this study done?
The main goal of this study was to see the safety
and immune response to a third dose of the high-
RSV (respiratory syncytial virus) can infect the
dose recipe of RSV OA vaccine in the same older
airways and lungs. RSV is spread from person to
adults.
person mostly by coughing and sneezing. It may
lead to a runny nose, fever, cough, difficulty in Study doctors also collected information about
breathing and loss of appetite. Infants and older potential side effects to the vaccines given in this
adults are most likely to have a severe RSV study. The results can be found in the section
infection. Vaccines may be a way to help protect “What were the side effects?”.
against RSV. They contain parts of RSV that
This report focuses on the results of the main
cannot cause infection. These parts help the
goals of the study. All results may be found in the
body make defenses, known as antibodies,
clinical results summary.
against RSV.
Who took part in this study?
122 older adults from United States and
Belgium.
60 years and older when they got
vaccinated.
72 women (59%)
50 men (41%)
Older adults could take part in the Older adults could not take part in the
study if they: study if they:
• received 2 doses of different recipes of • had a weak immune system
RSV OA vaccine in the previous study
• were bed-ridden
• were medically stable
• received any investigational product within 30
days before the study